AJP - Heart Myographs and Tissue organ baths
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Am J Physiol Heart Circ Physiol 257: H2033-H2035, 1989;
0363-6135/89 $5.00
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Clarke, J. G.
Right arrow Articles by Maseri, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Clarke, J. G.
Right arrow Articles by Maseri, A.

AJP - Heart and Circulatory Physiology, Vol 257, Issue 6 2033-H2035, Copyright © 1989 by American Physiological Society

ARTICLES

Endothelin is a potent long-lasting vasoconstrictor in men

J. G. Clarke, N. Benjamin, S. W. Larkin, D. J. Webb, G. J. Davies and A. Maseri
Division of Cardiovascular Medicine, Royal Postgraduate Medical School, Hammersmith Hospital, London, United Kingdom.

Endothelin, a 21-amino acid peptide synthesized by cultured porcine aortic endothelial cells, has recently been identified and shown to produce a potent and prolonged constriction of mammalian blood vessels in vitro. We have studied the effect of local infusion of this peptide on resistance and capacitance vessels of normal volunteers. Infusion of endothelin (5 pmol/min) reduced forearm blood flow by 39 +/- 7% from control observations. The maximum response was seen after approximately 55 min of infusion. After stopping the infusion, return of flow to basal values took approximately 120 min. This contrasts with the short onset and duration of action observed when angiotensin II was infused. During coinfusion studies, reversal by nicardipine (0.3-10 micrograms/min) occurred at similar concentrations in both endothelin-induced and angiotensin-induced flow reduction. This observation suggests that nicardipine nonspecifically antagonizes the flow-reducing effects of endothelin. A pattern of slow onset of constriction was found on local infusion of endothelin (5 pmol/min) into dorsal hand veins. During coinfusion of nicardipine (1.5 microgram/min), no reversal of endothelin-induced (5 pmol/min) constriction of dorsal hand veins occurred. The pharmacological profile of this peptide in the peripheral circulation of humans suggests that it may be involved in long-term regulation of vascular tone.


This article has been cited by other articles:


Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
D. W. Wray, S. K. Nishiyama, A. J. Donato, M. Sander, P. D. Wagner, and R. S. Richardson
Endothelin-1-mediated vasoconstriction at rest and during dynamic exercise in healthy humans
Am J Physiol Heart Circ Physiol, October 1, 2007; 293(4): H2550 - H2556.
[Abstract] [Full Text] [PDF]

Home page
 J. Appl. Physiol.Home page
J. Y. C. Tsang, W. J. E. Lamm, B. Neradilek, N. L. Polissar, and M. P. Hlastala
Endothelin receptor blockade does not improve hypoxemia following acute pulmonary thromboembolism
J Appl Physiol, February 1, 2007; 102(2): 762 - 771.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Heart Circ. Physiol.Home page
W. Johnson, A. Nohria, L. Garrett, J. C. Fang, J. Igo, M. Katai, P. Ganz, and M. A. Creager
Contribution of endothelin to pulmonary vascular tone under normoxic and hypoxic conditions
Am J Physiol Heart Circ Physiol, August 1, 2002; 283(2): H568 - H575.
[Abstract] [Full Text] [PDF]

Home page
 FASEB J.Home page
M. C. Y. HO, A. C. Y. LO, H. KURIHARA, A. C. H. YU, S. S. M. CHUNG, and S. K. CHUNG
Endothelin-1 protects astrocytes from hypoxic/ischemic injury
FASEB J, March 1, 2001; 15(3): 618 - 626.
[Abstract] [Full Text] [PDF]

Home page
 HypertensionHome page
F. E. Strachan, J. C. Spratt, I. B. Wilkinson, N. R. Johnston, G. A. Gray, and D. J. Webb
Systemic Blockade of the Endothelin-B Receptor Increases Peripheral Vascular Resistance in Healthy Men
Hypertension, January 1, 1999; 33(1): 581 - 585.
[Abstract] [Full Text] [PDF]

Home page
 CirculationHome page
C. J. Ferro, J. C. Spratt, W. G. Haynes, and D. J. Webb
Inhibition of Neutral Endopeptidase Causes Vasoconstriction of Human Resistance Vessels In Vivo
Circulation, June 16, 1998; 97(23): 2323 - 2330.
[Abstract] [Full Text] [PDF]

Home page
 StrokeHome page
T. Tatlisumak, R. A. D. Carano, K. Takano, T. J. Opgenorth, C. H. Sotak, M. Fisher, C. Y. Hsu, and W. Lin
A Novel Endothelin Antagonist, A-127722, Attenuates Ischemic Lesion Size in Rats With Temporary Middle Cerebral Artery Occlusion : A Diffusion and Perfusion MRI Study • Editorial Comment: A Diffusion and Perfusion MRI Study
Stroke, April 1, 1998; 29(4): 850 - 858.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
J. J. Maguire, R. E. Kuc, and A. P. Davenport
Affinity and Selectivity of PD156707, A Novel Nonpeptide Endothelin Antagonist, for Human ETA and ETB Receptors
J. Pharmacol. Exp. Ther., February 1, 1997; 280(2): 1102 - 1108.
[Abstract] [Full Text]

Home page
 NEJMHome page
E. R. Levin
Endothelins
N. Engl. J. Med., August 10, 1995; 333(6): 356 - 363.
[Full Text] [PDF]

Home page
 CirculationHome page
W. G. Haynes, F. E. Strachan, and D. J. Webb
Endothelin ETA and ETB Receptors Cause Vasoconstriction of Human Resistance and Capacitance Vessels In Vivo
Circulation, August 1, 1995; 92(3): 357 - 363.
[Abstract] [Full Text]

Home page
 CirculationHome page
D. Lyons, J. Webster, and N. Benjamin
Angiotensin II : Adrenergic Sympathetic Constrictor Action in Humans
Circulation, March 1, 1995; 91(5): 1457 - 1460.
[Abstract] [Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online